Biohaven Ltd. (BHVN) stock
BHVNNYSEPharmaceutical PreparationsFiscal year ends December 31
$13.24−0.56 (-4.06%)
Close on Nov 17, 2026Market cap $2.00BP/E –Yield –
Biohaven EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Biohaven's EPS for the twelve months ending Sep 30, 2026 was -$3.86. For fiscal 2025 it was -$6.86. The highest annual figure on record is -$3.01 in fiscal 2020.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.86 | – |
| FY2024 | Dec 31, 2024 | -$9.28 | – |
| FY2023 | Dec 31, 2023 | -$5.73 | – |
| FY2022 | Dec 31, 2022 | -$12.75 | – |
| FY2021 | Dec 31, 2021 | -$5.43 | – |
| FY2020 | Dec 31, 2020 | -$3.01 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.86 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.91 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.88 | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.21 | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.64 | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.94 | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.17 | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.85 | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.70 | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.64 | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.20 | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.81 | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.50 | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.32 | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.03 | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.31 | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.75 | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.16 | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.46 | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.32 | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.38 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?